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Glioblastoma multiforme (GBM) is the most common malignant brain tumor, which, despite combined
modality treatment, reoccurs and is invariably fatal for affected patients. Recently, a member of
the serine/threonine protein kinase D (PRKD) family, PRKD2, was shown to be a potent mediator of
glioblastoma growth. Here we studied the role of PRKD2 in U87MG glioblastoma cell migration and
invasion in response to sphingosine-1-phosphate (S1P), an activator of PRKD2 and a GBM mitogen.
Time-lapse microscopy demonstrated that random cell migration was signiﬁcantly diminished in
response to PRKD2 silencing. The pharmacological PRKD family inhibitor CRT0066101 decreased
chemotactic migration and invasion across uncoated or matrigel-coated Transwell inserts. Silencing
of PRKD2 attenuated migration and invasion of U87MG cells even more effectively. In terms of
downstream signaling, CRT0066101 prevented PRKD2 autophosphorylation and inhibited p44/42
MAPK and to a smaller extent p54/46 JNK and p38 MAPK activation. PRKD2 silencing impaired
activation of p44/42 MAPK and p54/46 JNK, downregulated nuclear c-Jun protein levels and decreased
c-JunS73 phosphorylation without affecting the NFκB pathway. Finally, qPCR array analyses revealed
that silencing of PRKD2 downregulates mRNA levels of integrin alpha-2 and -4 (ITGA2 and -4),
plasminogen activator urokinase (PLAU), plasminogen activator urokinase receptor (PLAUR), and matrix
metallopeptidase 1 (MMP1). Findings of the present study identify PRKD2 as a potential target to
interfere with glioblastoma cell migration and invasion, two major determinants contributing to
recurrence of glioblastoma after multimodality treatment.
& 2013 Elsevier Inc. Open access under CC BY-NC-ND license. Introduction
Glioblastoma multiforme (GBM; astrocytoma WHO grade IV) is
the most common and malignant type of primary brain tumors.Biology and Biochemistry
az.at (W. Sattler).
CC BY-NC-ND license. GBM is characterized by high proliferative rate, aggressive invasive-
ness and insensitivity to radio- and chemo-therapy. The median
survival in patients with newly diagnosed GBM following treatment
with surgery, radio- and chemo-therapy is approximately 15 months, Medical University of Graz, Harrachgasse 21, 8010 Graz, Austria.
E X P E R I M E N T A L C E L L R E S E A R C H 3 1 9 ( 2 0 1 3 ) 2 0 3 7 – 2 0 4 82038[1]. Comprehensive genetic analyses of GBMs identiﬁed a number of
mutations affecting three major pathways: the receptor tyrosine
kinase (RTK) pathway and its downstream oncogenic signaling by
PI3K/AKT/mTOR and RAS/MAPK, the p53, and the retinoblastoma
protein pathway [2,3]. Modiﬁcations of these pathways drive
gliomagenesis by mediating proliferation, migration, angiogenesis,
survival, and deregulation of apoptotic signaling.
Three major reasons account for therapy resistance: the pre-
sence of the blood–brain barrier that restricts drug distribution to
the brain, the heterogeneity of the tumor that consists of cell
populations with different drug sensitivities, and the propensity
of the tumor cells to inﬁltrate the normal brain leading to
recurrences [4]. Individual cells or groups of cells can detach
from the primary tumor and migrate to distant sites within
normal brain structures [5]. The invasive nature of GBM has been
frequently implicated as a key feature of resistance to therapy [6].
GBM cell invasion is a multistep, but highly coordinated process
that starts with the degradation of surrounding matrix proteins
by matrix metalloproteinases (MMPs) [7]. Cells must then detach
from their neighboring cells and matrix components in order to
gain motility and move through healthy brain tissue. During this
process cells must form new and release ‘old’ focal adhesions and
constantly reorganize their cytoskeleton. This process is receptor
mediated and involves complex interactions between integrins,
receptor tyrosine kinases and (lipid-mediated) activation of
downstream signaling cascades [7].
A core-signaling pathway in migration and invasion is the
phospholipase C pathway catalyzing the formation of inositol
1,4,5-triphosphate (IP3) and diacylglycerol (DAG) leading to
activation of the PKC family [8]. One of the targets activated by
DAG and different PKC isoforms is the protein kinase D (PRKD)
family [9]. The PRKD family is located downstream of PKC and
belongs to the calcium/calmodulin dependent protein kinase
superfamily and comprises of three isoforms PRKD-1, -2, and -3.
Being major players in cell proliferation, motility, and angiogen-
esis, PRKD members received considerable interest as potential
anti-cancer targets. Although the evidence for PRKD1 in tumor
development is somewhat ambiguous (for review see [10]),
PRKD1 is overexpressed in pancreatic ductal adenocarcinoma
[11,12] and pharmacological inhibition of PRKD1 was shown to
impair pancreatic ductal adenocarcinoma proliferation [13]. Both,
PRKD1 and PRKD3 are involved in the progression and invasion
of prostate cancer [14,15]. PRKD2 mediates NFκB activation in
leukemia cells [16] and expression levels correlate with the state
of de-differentiation in malignant human lymphoma [17]. Only
recently it was demonstrated that PRKD2 is a potent regulator of
glioblastoma cell growth in vitro and in vivo [18].
There is ample evidence that PRKD members are regulators of cell
migration and invasion. PRKD1 controls ﬁbroblast motility by
modulating membrane trafﬁc from the trans-Golgi network to the
plasma membrane [19]. PRKD1 is also involved in integrin transport
to focal adhesions, thereby affecting cell migration [20]. PRKD
members phosphorylate downstream targets that are involved in cell
motility including cortactin [21], slingshot 1 like [22], and Par-1 [23].
PRKD1 regulates MMP expression in breast cancer cells [24] that
control cell migration and invasion and play an important role in
glioblastoma cell invasion [25]. PRKD signaling starts with ligand
binding to seven-transmembrane or tyrosine kinase receptors that
activate PLCβ or PLCγ. Activation of this pathway results in the
generation of DAG and IP3. Membrane-associated DAG binds andactivates PKC, which then phosphorylates two serine residues in the
activation loop of PRKDs [9]. One of the G protein-coupled receptor
(GPCR) ligands that activate PRKD is sphingosine-1-phosphate (S1P), a
bioactive lipid that signals via ﬁve cognate G protein-coupled
receptors termed S1P1–5 [26]. Exogenously added S1P is a potent
glioblastoma mitogen and enhances glioblastoma invasiveness
[27–31]. Accumulating evidence suggests that S1P is involved in
cancer progression including cell transformation, cell survival, cell
migration and metastasis, and neoangiogenesis of the tumor micro-
environment [26]. In particular PRKD2 that is highly expressed in
glioblastoma [18], has critical roles in vascular biology and angiogen-
esis [32]. PRKD2 mediates vascular endothelial growth factor (VEGF)-
induced endothelial cell (EC) proliferation and migration and reg-
ulates the expression of VEGF receptor-2 and the production of
cytokines in ECs [33]. Furthermore, PRKD2 controls hypoxia-induced
VEGF synthesis and secretion by tumor cells and regulates VEGF
signaling in tumor-associated endothelial cells [34]. In addition, strong
PRKD2 expression in the tumor endothelium of microvascular pro-
liferations in glioblastoma was reported [18]. Only recently a splice
variant of human calcium and integrin-binding protein 1 was
identiﬁed as a novel PRKD2 substrate and interactor that contributes
to tumor growth in vivo by promoting angiogenesis [35].
In the present study we tested the hypothesis that PRKD2
regulates U87MG glioblastoma cell migration and invasion.
Pharmacological inhibition and PRKD2 silencing impaired migra-
tory, chemotactic, and invasive behavior of non-stimulated and
S1P-stimulated U87MG cells and attenuated activation of MAPK
pathways. Gene expression analysis by RT proﬁler PCR arrays
revealed altered expression levels of several genes involved in
GBM motility and migration.Materials and methods
Cell culture supplies were from Gibco (Invitrogen, Vienna, Austria),
PAA Laboratories (Linz, Austria) and Costar (Vienna, Austria). Horse-
radish peroxidase (HRP)-labeled goat anti-rabbit IgG and mouse
anti-actin were from Sigma (Vienna, Austria). Sphingosine-1-phos-
phate, mouse anti-PRKD2, rabbit anti-NFκB (p50 and p65), rabbit
anti-lamin A/C and HRP-labeled goat anti-mouse IgG were from
Santa Cruz Biotechnology (CA, USA). Rabbit anti-p44/42 MAPK,
rabbit anti-phospho-p44/42 MAPK (Thr202/Tyr204), rabbit anti-
p38 MAPK, rabbit anti-phospho-p38 MAPK (Thr180/Tyr182), rabbit
anti-SAPK/JNK, rabbit anti-phospho-SAPK/JNK (Thr183/Tyr185),
rabbit anti-c-Jun, rabbit anti-phospho-c-Jun (Ser63 and Ser73), and
rabbit anti-GAPDH were from Cell Signaling Technology (MA, USA).
Rabbit anti-phospho-PRKD2 (Ser876 in the autophosphorylation
domain) was from Abcam (Cambridge, UK). SuperSignal Western
blot detection reagent kit was from Pierce (Thermo Scientiﬁc, MA,
USA) and ECL Plus Western Blotting Reagents were form Amersham
Biosciences (Vienna, Austria). SuperScript II Reverse Transcriptase
and Oligofectamine were from Invitrogen (Vienna, Austria). Random
hexamer primer was from Thermo Scientiﬁc (MA, USA). RNeasy Plus
Kit, QuantiFast SYBR Green PCR kit, QuantiTect primer assays
Hypoxanthine phosphoribosyltransferase 1 (Hs_HPRT_1_SG; inter-
nal standard), Protein Kinase D2 (Hs_PRKD2_1_SG), Integrin alpha 2
(Hs_ITGA2_1_SG), Integrin alpha 4 (Hs_ITGA4_1_SG), Plasminogen
activator, urokinase (Hs_PLAU_1_SG), Plasminogen activator,
urokinase receptor (Hs_PLAUR_1_SG), Matrix metalloproteinase 1
(Hs_MMP1_1_SG) and the siRNA speciﬁcally targeting PRKD2
E X P E R I M E N T A L C E L L R E S E A R C H 3 1 9 ( 2 0 1 3 ) 2 0 3 7 – 2 0 4 8 2039(Hs_PRKD2_5 and Hs_PRKD2_6) were from Qiagen (Hilden,
Germany) and non-targeting siRNA (scrambled siRNA) was from
Dharmacon (Thermo Scientiﬁc, MA, USA). BD Matrigel Invasion
Chamber (8 mM pore size) and Control Inserts (8 mM pore size)
were from BD Biosciences Europe (Erembodegem, Belgium).
CRT0066101 was from Cancer Research Technology (London, UK).
Cell culture
U87MG cells were from ATCC (HTB 14) and maintained in
Dulbecco´s modiﬁed Eagle medium (DMEM)/high glucose supple-
mented with 10% FCS and 2% penicillin/streptomycin. Cells were
grown at 37 1C under 5% CO2.
RNA interference
U87MG cells were seeded at 40,000 cells per well into 12 well
plates and grown for 24 h. Transfection of siRNA (20 nM) was
performed using Oligofectamine according to the manufacturer's
instructions (Invitrogen). Untreated cells (control) and cells
transfected with Oligofectamine alone (mock) or non-targeting
siRNA (scrambled siRNA) were used as controls. The siRNAs
speciﬁcally targeting the four known transcript variants of PRKD2
(NM_001079880, NM_001079881, NM_001079882, NM_016457)
were from Qiagen (Hs_PRKD2_5 and Hs_PRKD2_6) and scrambled
siRNA (siSCR) was from Dharmacon. At the indicated time points
cells were trypsinized, lysed and protein or RNA extracts were
collected.
Motility assay
For time-lapse microscopy untreated cells and cells transfected
with siSCR and siPRKD2_5 were seeded on 24-well tissues. Two
days post transfection images were acquired every 20 min for
24 h at ﬁve different positions of each well using a Zeiss Cell
Observer microscope. Cell motility of 50 cells per treatment group
was assessed using the Manual Tracking Macro and the Chemo-
taxis plugin of ImageJ. Mean velocity7SEM, the mean accumu-
lated distance7SEM, and the mean Euclidian distance7SEM of
the analyzed cells were calculated. *po0.05, **po0.01 in compar-
ison to siSCR
Chemotaxis assay
The migration assay was performed using cell culture inserts with
PET membrane (8 mm pore size). U87MG cells were seeded at
50,000 cells per well into 12 well culture plates, grown for 24 h
and transfected with speciﬁc siRNA (20 nM). Two days after
transfection, cells were harvested and 50,000 cells in medium
+0.5% FCS were added to the upper compartment of the cell
culture inserts. Where speciﬁed, 1 mM CRT0066101 was added to
the upper compartment of the cell culture inserts. The lower
compartment was ﬁlled with medium+10% FCS, medium+0.5%
FCS or serum free medium containing 1 mM S1P. After two days of
incubation at 37 1C, the upper surface of the membrane was
wiped with a cotton swab to remove non-migratory cells. Cells
that migrated to the bottom side of the membrane were ﬁxed
with methanol, stained with toluidine blue for 2 min and the
membrane was washed twice with water. Membranes were
placed on a glass slide, and from each membrane six ﬁelds werecounted using an optical microscope (20 magniﬁcation). Assays
were performed in quadruplicate for each condition. Data are
presented as mean7SEM. ***po0.001, **po0.01, *po0.05 in
comparison to control or siSCR.
Invasion assay
For the invasion assay cell culture inserts with PET membrane
(8 mm pore size) coated with matrigel were used. U87MG cells
were transfected with speciﬁc siRNA (20 nM) and two days post
transfection, cells were harvested. After rehydration of the
matrigel with medium, 50,000 cells in medium+0.5% FCS or
50,000 cells in medium+0.5% FCS+1 mM CRT0066101 were added
to the upper compartment of the cell culture inserts. The lower
compartment was ﬁlled with medium+10% FCS, medium+0.5%
FCS or serum free medium containing 1 mM S1P or 2.5 mM S1P
(2.5 mM S1P were readded after 24 h). After two days of incuba-
tion at 37 1C, cells that migrated through the matrigel were
quantiﬁed as described above for the chemotaxis assay. Data are
presented as mean7SEM. ***po0.001, **po0.01 in comparison to
control or siSCR.
PRKD2 and MAPK activation
Prior to measurement of PRKD2 or MAPK activation, U87MG cells
were serum-starved for 3 h. Cells were incubated in the absence
or presence of S1P for the indicated times and concentrations.
Where speciﬁed, cells were incubated with CRT0066101 over
night before S1P treatment. After incubation cells were lysed and
protein extracts were collected.
Western blot analysis
For immunoblotting, whole cell extracts and/or cytoplasmic/
nuclear extracts (prepared with the NE-PER Nuclear and Cyto-
plasmic Extraction Reagents from Pierce) were used. Protein
concentration was measured using the Bradford protein assay.
Equal protein aliquots were loaded, separated on SDS-PAGE under
reducing conditions, transferred to PVDF membranes and immu-
nochemical detection of p44/42 MAPK, phospho-p44/42 MAPK,
p38 MAPK, phospho-p38 MAPK, JNK, phospho-JNK, c-Jun, phos-
pho-c-Jun, NFκB, PRKD2, and phospho-PRKD2 was performed
with speciﬁc primary antibodies. Immunoreactive bands were
visualized with HRP-conjugated goat anti-rabbit or goat anti-
mouse IgG and the ECL detection system. Quantiﬁcation of protein
expression (relative optical density) was normalized to appro-
priate loading controls (lamin A/C, actin, GAPDH) and phosphor-
ylation of MAPKs was referred to total MAPK protein.Human Cancer PathwayFinder PCR array
Total RNA of mock and siPRKD2_5 transfected U87MG cells
was isolated in triplicates on day three post transfection. cDNA
synthesis and RT-PCR arrays were performed according to the
manufacturer's instructions. For data analyses the web-based
software package provided by SABiosiences was used. Raw data
were normalized to the most stably expressed housekeeping gene
(ribosomal protein L13a) and fold-changes in gene expression
were calculated using the ΔCt method. Genes with at least 1.8 fold
10 siPRKD2_5io
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Cells were transfected with speciﬁc siRNAs, lysed and RNA
extracts were collected two or four days post transfection. Total
RNA was isolated using the RNeasy Kit. Aliquots of 3 mg of total
RNA were reverse transcribed using SuperScript II Reverse Tran-
scriptase and random hexamer primers according to the manu-
facturer's protocol (Invitrogen). Real-time PCRs were performed
with an Applied Biosystems 7900HT Fast Real Time PCR System,
the QuantiFast SYBR Green PCR kit and QuantiTect Primer Assays.
Hypoxanthine phosphoribosyltransferase 1 (HPRT) was used as
housekeeping gene. The following QuantiTect primer assays were
used: Hypoxanthine phosphoribosyltransferase 1 (Hs_HPRT_1_SG;
internal standard), Protein Kinase D2 (Hs_PRKD2_1_SG), Integrin
alpha 2 (Hs_ITGA2_1_SG), Integrin alpha 4 (Hs_ITGA4_1_SG), Plas-
minogen activator, urokinase (Hs_PLAU_1_SG), Plasminogen activa-
tor, urokinase receptor (Hs_PLAUR_1_SG), Matrix metalloproteinase
1 (Hs_MMP1_1_SG).day 3
s s s s
day 5
Fig. 1 – Efﬁcacy of PRKD2 silencing. Knockdown of PRKD2
expression in U87MG cells was performed by RNA interference
using two different siRNA constructs (Oligofectamine was used
to transfect 20 nM siRNA). Silencing efﬁcacy was analyzed by
(A) qPCR two and four days post transfection and (B) Western
blotting three and ﬁve days post transfection. Results in (A)
represent mean7SD of three different experiments. Results in
(B) show one representative Western blot out of ﬁveStatistical analyses
Data are presented as mean7SEM. One-way ANOVA followed by
Bonferroni post-hoc comparison test was used for analysis of
statistical signiﬁcance. ***po0.001, **po0.01, *po0.05.
Statistical signiﬁcance of differences in mRNA expression levels
was analyzed using the relative expression software tool (REST©,
http://www.gene-quantiﬁcation.de/rest.html) using a pair-wise
ﬁxed reallocation test [36].independent experiments. Numbers represent relative optical
densities of PRKD2 protein normalized to loading controls.Results
PRKD2 silencing inhibits migration and invasion of U87MG
glioma cells in response to S1P
Initially we determined the efﬁcacy of PRKD2 (Gene ID: 25865)
silencing in U87MG cells using two different 21mer siRNA
constructs. As shown in Fig. 1A, PRKD2 silencing led to reduced
mRNA expression. Maximum knockdown was reached at day 2
with relative mRNA expression levels of 0.28 for siPRKD2_5 and
0.12 for siPRKD2_6. On protein level, expression was efﬁciently
decreased by 95% up to day four with both siRNAs. A scrambled
control siRNA had no effect on PRKD2 protein expression (Fig. 1B).
Next, we examined the effect of PRKD2 silencing on random 2D
migration of U87MG cells by time-lapse video microscopy. By
analyzing the tracks of 50 individual cells per group the velocity,
accumulated distance, and Euclidian distance was calculated. The
directionality of cell movement was determined as the Euclidian
distance divided by the accumulated distance. As shown in
Fig. 2A, silencing of PRKD2 resulted in a small, but statistically
signiﬁcant (po0.05) reduction of migration speed as compared
to cells transfected with scrambled siRNA (0.38 vs. 0.42 mm/h;
siPRKD2_5 vs. siSCR). Both, accumulated (540 vs. 630 mm;
siPRKD2 vs. siSCR) and Euclidian (125 vs. 195 mm; siPRKD2 vs.
siSCR) distance was signiﬁcantly reduced in response to RNAi
(Fig. 2B and C). In addition, the directionality of cell movementwas attenuated in PRKD2 silenced cells (0.23 vs. 0.31; siPRKD2 vs.
siSCR).
To determine the impact of pharmacological inhibition (using
the PRKD family inhibitor CRT0066101) or PRKD2 silencing on
chemotactic migration, Transwell inserts were used. Directed
migration was analyzed in medium containing FCS (10% or 0.5%)
or S1P (1 mM complexed to BSA) in the lower chamber. Repre-
sentative micrographs of transmigrated cells are shown in Fig. 3A.
These microscopic pictures indicate that both, pharmacological
inhibition and RNAi of PRKD2 attenuates cell migration across
uncoated Transwell inserts. Quantitative evaluation of these
experiments showed that a reduction of FCS from 10% to 0.5%
reduced the number of migrated non-transfected cells by 80%
(220 vs. 45 cells/ﬁeld). The addition of S1P to the lower chamber
increased the migration by 2-fold in comparison to 0.5% FCS
(Fig. 3B).
CRT0066101 reduced transmigration in 10% FCS by 24% (167 vs.
220 cells/ﬁeld) and in response to S1P by 23% (71 vs. 92 cells/
ﬁeld). Under unphysiological, serum free conditions migration in
the presence of CRT0066101 was increased by 2.1-fold. Transfec-
tion with siSCR yielded essentially the same results as observed
with non-transfected cells. In contrast, chemotactic migration was
signiﬁcantly attenuated in PRKD2 silenced cells under all experi-
mental conditions applied. Compared to siSCR, PRKD2 silencing
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Fig. 2 – Interference with PRKD2 expression impairs random migration of U87MG cells. For time-lapse microscopy untreated cells
and cells transfected with siSCR or siPRKD2_5 were seeded on 24-well tissues. Two days post transfection images were acquired
every 20 min for 24 h at ﬁve different positions of each well. Cell motility of 50 cells per treatment group was assessed using the
Manual Tracking Macro and the Chemotaxis plugin of ImageJ. The (A) mean velocity, (B) mean accumulated distance and (C) the
mean Euclidian distance was calculated. *po0.05, **po0.01 in comparison to siSCR (1way ANOVA).
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Fig. 3 – Interference with PRKD2 expression reduces chemotactic migration and the invasive potential of U87MG cells. Untreated
cells, cells transfected with siSCR and siPRKD2_5 and cells treated with 1 lM CRT0066101 were allowed to migrate across uncoated
or matrigel-coated Transwell inserts. The lower chamber was loaded with medium containing FCS (10 or 0.5%; v/v) or S1P (1 lM or
2.5 lM; serum free). Cells that migrated to the bottom side of the membrane were ﬁxed with methanol, stained with toluidine blue
for 2 min and the membrane was washed twice with water. Cells in six ﬁelds from each membrane were counted using an optical
microscope (20x magniﬁcations). (A) Representative images of migrated cells. Quantitative analysis of cell migration across (B)
uncoated or (C) matrigel-coated Transwell inserts. Data are presented as mean7SEM. Assays were performed in quadruplicate for
each condition. ***po0.001, **po0.01 in comparison to control or siSCR (1way ANOVA).
E X P E R I M E N T A L C E L L R E S E A R C H 3 1 9 ( 2 0 1 3 ) 2 0 3 7 – 2 0 4 8 2041impaired chemotactic migration by 51, 30 and 45% (10% or 0.5%
FCS, and 1 mM S1P, respectively; Fig. 3B).
We further assessed the impact of CRT0066101 and PRKD2
silencing on invasive properties of U87MG cells in matrigel-coated
Transwell inserts. Under control conditions a reduction of FCS from
10% to 0.5% in the lower chamber completely abrogated cell invasion
while in the presence of S1P 3 (1 mM) and 10 cells (2.5 mM) invadedper ﬁeld (Fig. 3C). CRT0066101 inhibited invasion by 49% and 60%
(10% FCS and 2.5 mM S1P, respectively). As shown for chemotactic
migration, CRT0066101 increased invasion under serum free condi-
tions (0 vs. 12 cells/ﬁeld). Transfection with siSCR slightly diminished
(6.6%) invasion. Silencing of PRKD2 signiﬁcantly reduced the number
of transmigrated cells by 69 (10% FCS), 95 (1 mM S1P) and 78%
(2.5 mM S1P; Fig. 3C) in comparison to siSCR.
E X P E R I M E N T A L C E L L R E S E A R C H 3 1 9 ( 2 0 1 3 ) 2 0 3 7 – 2 0 4 82042Exogenous S1P induces activation of PRKD2 and MAPK
pathways
PRKD family members are activated in response to extracellular
stimuli, including S1P, thereby affecting various downstream
signaling cascades implicated in tumor biology [10]. Thus, we
ﬁrst analyzed activation of PRKD2 and MAPK family members in
response to S1P. As shown in Fig. 4 the addition of exogenous,
BSA-complexed S1P resulted in a concentration- and time-
dependent activation of PRKD2, p44/42 MAPK, p54/46 JNK and
p38 MAPK. Autophosphorylation levels of PRKD2 at S876 were
continuously increasing in response to S1P (1 nM to 10 mM).
Activation of the MAPK family members occurred at comparable
S1P levels (10–100 nM) as observed for PRKD2 (Fig. 4A). Stimulation
with S1P for increasing times revealed maximal activation of PRKD2
after 5 min decreasing to baseline after 60 min. Time-dependent
activation of p44/42 and p38 MAPKs followed comparable kinetics aspp44/42
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are shown.observed for PRKD2 (Fig. 4B). p54/46 JNK activation reached its
maximum at later time points (15 and 30min) and was still elevated
at 60min.
Pharmacological inhibition and silencing of PRKD2
attenuates downstream MAPK pathways
In the next set of experiments the outcome of CRT0066101 and
PRKD2 silencing on S1P-mediated activation of MAPK family
members was studied. CRT0066101 (0.35 and 1 mM) attenuated
basal and S1P-induced autophosphorylation of PRKD2, p44/42
MAPK and to a lesser extent p54/46 JNK and p38 MAPK (Fig. 5A).
PRKD2 silencing signiﬁcantly diminished phosphorylation of
p44/42 MAPK and p54/46 JNK under basal or S1P-stimulated
conditions (Fig. 5B), whereas phosphorylation of p38 MAPK
was slightly impaired by scrambled siRNA. Neither CRT0066101
nor RNAi affected the levels of non-phosphorylated p54/46 JNK,0 
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Fig. 5 – Pharmacological inhibition and silencing of PRKD2 impairs MAPK signaling and c-Jun regulation but does not affect the
NFκB pathway. Cells were incubated with (A) CRT0066101 at the indicated concentrations overnight or (B) transfected with
scrambled siRNA (S) and siPRKD2_5 (P5) for two days and activated with 1 lM BSA-complexed S1P for the indicated times. Protein
levels of PRKD2 and MAPK family member activation were analyzed as described in Fig. 4. Results of one experiment out of three
(that provided similar results) are shown. (C) c-Jun expression and activation was analyzed in nontransfected and transfected
(siSCR, siPRKD2_5) cells in the absence or presence of S1P (1 lM, 5 min). Nuclear lysates were separated by SDS-PAGE (10 lg
protein/lane) and transferred to PVDF membrane. Total c-Jun expression and c-Jun protein activated by phosphorylation at Ser63
or Ser73 were analyzed using speciﬁc antibodies. Results of one experiment out of three are shown. (D) Cytosolic and nuclear
PRKD2, pPRKD2, and NFκB (p50 and p65) expression was analyzed in nontransfected and transfected (siSCR, siPRKD2_5) cells
under unstimulated and stimulated (1 lM S1P for 5 min) conditions. Cytosolic and nuclear protein fractions were separated by
SDS-PAGE (10 lg protein/lane) and transferred to PVDF membrane. Immunoreactive bands were detected using rabbit antibodies.
One experiment out of two is shown.
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silencing of PRKD2 resulted in downregulation of signaling
cascades that are implicated in glioblastoma migration and
invasion.
JNK and ERK direct distinct cellular activities even though they
share a number of common substrates, including severaltranscription factors. In PC12 cells activation of the ERK pathway
results in stimulation of both c-Jun synthesis and c-Jun phosphor-
ylation, whereas the JNK pathway triggers phosphorylation [37].
Western blot analysis of nuclear cell extracts (c-Jun was unde-
tectable in the cytosolic fraction, data not shown) demonstrated
that PRKD2 silencing attenuates the level of total c-Jun protein
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phosphorylated c-Jun revealed that PRKD2 silencing was without
effects on c-JunS63 but slightly downregulates c-JunS73 phosphor-
ylation under basal and S1P stimulated conditions (Fig. 5C).
In prostate cancer cells PRKD-2 and -3 were shown to promote
cell invasion via the NFκB pathway [15]. To investigate whether
this pathway is affected by PRKD2 silencing in U87MG cells
we have analyzed NFκB levels in cytosolic and nuclear fractions
of unstimulated and S1P-stimulated cells. Data shown in Fig. 5D
demonstrate that PRKD2 silencing was without effect on protein
levels of the NFκB-associated subunits p65 and p50 in
U87MG cells.d2 d4 d2 d4 d2 d4 d2 d4 d2 d4
0.1N
Fig. 6 – Silencing of PRKD2 impacts on U87MG gene expression.
PRKD2 expression was silenced with siPRKD2_5. Two and four
days post transfection target gene expression was analyzed by
qPCR using validated primer pairs. Hypoxanthine
phosphoribosyltransferase 1 (HPRT) was used as housekeeping
gene. Relative gene expression of target genes is presented in
relation to mock transfection. Results represent mean7SD
from three independent experiments. Gene expression ratios
were calculated by REST as described in Materials and
methods.PRKD2 silencing in U87MG cells affects mRNA expression
levels of genes involved in glioma migration and invasion
To get an indication about downstream targets of PRKD2 under
basal conditions, pathway analysis by qPCR array analysis was
performed. Out of 28 genes involved in adhesion, invasion and
metastasis, 5 genes (ITGA2, ITGA4, MMP1, PLAU, and PLAUR)
exhibited at least a 1.8-fold change in mRNA expression levels in
response to PRKD2 silencing compared to mock transfected cells
(Table 1). Altered expression levels of these ﬁve products wereTable 1 – Alphabetical list of human genes related to adhesion, i
(Human Cancer PathwayFinder) and their regulation in response
Name of gene Gene
Integrin, alpha 1 ITGA
Integrin, alpha 2 ITGA
Integrin, alpha 3 ITGA
Integrin, alpha 4 ITGA
Integrin, alpha V ITGAV
Integrin, beta 1 ITGB
Integrin, beta 3 ITGB
Integrin, beta 5 ITGB
Melanoma cell adhesion molecule MCA
Met proto-oncogene MET
Matrix metallopeptidase 1 MMP
Matrix metallopeptidase 2 MMP
Matrix metallopeptidase 9 MMP
Metastasis associated 1 MTA1
Metastasis associated 1 family, member 2 MTA2
Metastasis suppressor 1 MTSS
Non-metastatic cells 1, protein (NM23A) expressed in NME
Non-metastatic cells 4, protein expressed in NME
Plasminogen activator, urokinase PLAU
Plasminogen activator, urokinase receptor PLAU
Pinin, desmosome associated protein PNN
S100 calcium binding protein A4 S100
Serpin peptidase inhibitor, member 5 SERP
Serpin peptidase inhibitor, member 1 SERP
Spleen tyrosine kinase SYK
TIMP metallopeptidase inhibitor 1 TIMP
TIMP metallopeptidase inhibitor 3 TIMP
Twist homolog 1 TWIS
The table lists the genes involved in adhesion and invasion that were analyze
individual gene expression in PRKD2 silenced U87MG cells compared to mock
calculated by Student's t-test of the replicate 2\widehat (ΔCt) values for eac
downregulation of genes. Only target genes regulated41.8 fold were consider
too low for analyses.conﬁrmed by qPCR (Fig. 6). The relative mRNA expression levels
of ITGA2, ITGA4, PLAU, and PLAUR after transfection with
siPRKD2_5 were reduced up to 0.36, 0.61, 0.53, and 0.70,nvasion and metastasis from the RT Proﬁler Pathway Array
to PRKD2 silencing using siPRKD2_5.
symbol Accession no Fold regulation
1 NM_181501 −1.11
2 NM_002203 −3.11*
3 NM_002204 1.35*
4 NM_000885 −1.93*
NM_002210 1.49*
1 NM_002211 −1.01
3 NM_000212 1.30*
5 NM_002213 1.48*
M NM_006500 −1.32*
NM_000245 −1.14
1 NM_002421 −4.00*
2 NM_004530 1.63*
9 NM_004994 low expression
NM_004689 −1.23*
NM_004739 −1.18*
1 NM_014751 −1.32*
1 NM_000269 −1.23*
4 NM_005009 1.00
NM_002658 −2.69*
R NM_002659 −1.92*
NM_002687 −1.40*
A4 NM_002961 1.11*
INB5 NM_002639 low expression
INE1 NM_000602 −1.34*
NM_003177 low expression
1 NM_003254 −1.09*
3 NM_000362 low expression
T1 NM_000474 1.45*
d by the RT² Proﬁler Array system. Data represent the fold-regulation of
transfected cells. Data were evaluated from three biological replicates and
h gene (*p≤0.05). Positive values indicate upregulation, negative values
ed for further qPCR analyses. Relative expression levels of four genes were
E X P E R I M E N T A L C E L L R E S E A R C H 3 1 9 ( 2 0 1 3 ) 2 0 3 7 – 2 0 4 8 2045respectively. The most prominent effect of PRKD2 silencing was
seen for the expression of MMP-1 with a maximum decrease of
mRNA levels to 0.22 on day 2. At day 4 post silencing most of
these effects were reduced, with exception of PLAU, which was
upregulated 1.9-fold.Discussion
The acquisition of cell motility is a key property of glioblastoma
cells contributing to the dismal perspectives for affected patients.
Work presented here identiﬁes a S1P/PRKD2/MAPK signaling
pathway that contributes to GBM cell migration and invasion.
Our results show that S1P activates PRKD2 and induces a
migrational and invasive response, which is attenuated in
response to PRKD2 silencing (Figs. 2–4). Accumulating evidence
suggests that S1P and S1P receptors are regulators of GBM
growth, migration, and invasion via outside-in or inside-out
signaling [38]. S1P signal transduction is mediated via ﬁve G
protein-coupled receptors (S1P1–5) [26]. Of these, S1P1–3 and S1P5
are expressed in glioblastoma cell lines and tissue [39,40]. S1P1–3
couple to the PLC/PKC pathway (via Gi and Gq) and are therefore
candidates that are able to induce PRKD2 activation as observed
during the present study (Fig. 4). Exogenously added S1P
enhances glioblastoma invasiveness [30,31] and microarray ana-
lyses have shown that upregulation of proteases by S1P could
contribute to invasive properties of GBM cells [41]. S1P directly
regulates uPAR expression in GBM cells thereby increasing inva-
siveness [31].
During carcinogenesis alterations in cell morphology and gene
expression and the disruption of cell–cell adhesions promote
cellular motility and invasiveness [42]. We show that PRKD2
silencing resulted in decreased motility and invasiveness of
U87MG cells (Fig. 3), which in principle can be a direct effect
and/or result from signaling events downstream of PRKD2. Along
this line we provide evidence that pharmacological inhibition
(CRT0066101; a small molecule inhibitor of the PRKD family that
blocks pancreatic cancer; Ref. [13]) or silencing of PRKD2 results
in impaired activation of MAPK pathways (Fig. 5A, B). This is in
agreement with other reports demonstrating MAPK activation in
a PRKD-dependent manner [43–45] mediating pro-proliferative
properties as speciﬁcally reported for PRKD2 in glioblastoma [18].
However, MAPK signaling is also centrally involved in several
other steps of tumor development. Phorbolester-mediated activa-
tion of the p44/42 MAPK pathway was shown to induce migration
and invasion of GBM cell [46]. p44/42 MAPK is essential for
integrin expression [47] and p44/42-dependent phosphorylation
of myosin light chain kinase, calpain, focal adhesion kinase, or
paxillin promotes cancer cell migration (for review see Ref. [48]).
p44/42 MAPK activation positively regulates uPAR expression
[49], induces the expression of MMP-1 [25], and enhances 3D
invasion of pancreatic cancer cells via MMP-1 expression [50].
Thus, decreased p44/42 MAPK signaling as observed here in
response to PRKD2 silencing is compatible with altered gene
expression patterns as described below.
The second MAPK pathway that was attenuated in response to
CRT0066101 and PRKD2 silencing during the present study is the
p54/46 JNK pathway (Fig. 5A, B). JNK signaling plays a pivotal role
in GBM invasion as pharmacological inhibition reduces invasive
properties [51]. Importantly, pharmacological inhibition of theJNK pathway in vivo depletes self-renewing and tumor-initiating
glioblastoma stem cell population [52,53]. Such a targeted phar-
macological approach could eliminate tumor initiating GBM cells
that inﬁltrate deep into unresectable brain regions. In this context
it is noteworthy that PRKD2 was identiﬁed in the phosphopro-
teome of EGF-activated human glioblastoma-initiating cells [54].
These ﬁndings make it tempting to speculate that PRKD2 not only
plays a role in primary GBM [18] but also could contribute to
tumor recurrence via GBM-initiating cells.
The c-Jun protein, a member of the AP-1 transcription factor
family, activates several events required for tumor progression. In
general, AP-1 proteins demand MAPK-derived phosphorylation to
form transcriptionally active complexes. External stimuli, includ-
ing growth factors, cytokines and cell stress, can cause a MAPK-
dependent increase in c-Jun transcription as shown for p44/42
MAPK [37], p54/46 JNK [55], and p38 MAPK [56]. In addition to
transcriptional activation, MAPK-induced phosphorylation contri-
butes to the stability of c-Jun protein. Phosphorylation by JNK
enhances protein stability via protection from ubiquitination [57],
whereas constitutively active p44/42 MAPK increases c-Jun sta-
bility via inactivation of glycogen kinase 2 in melanoma cells [58].
Thus, it is reasonable to assume that sustained decrease of p44/42
MAPK and/or p54/46 JNK activation is (at least in part) respon-
sible for decreased c-Jun levels as observed during the present
study (Fig. 5C). Additionally, direct phosphorylation of c-Jun by
PRKD2 may contribute to c-Jun regulation [59]. Of note, c-Jun
accumulation is elevated in human glioblastoma and the migra-
tion and invasion capacity of U87MG cells is signiﬁcantly reduced
in response to c-Jun silencing [60]. In addition, c-Jun, as a
component of the AP-1 transcription factor complex, regulates
the expression of integrins [61], urokinase plasminogen activator
receptor [62], and matrix metalloproteinases [63] that facilitate
growth, invasion, and metastasis of GBM cells.
Array and qPCR analyses performed during the present study
identiﬁed reduced expression levels of ITGA-2 and -4 (which
encode integrin alpha2 and -alpha4, respectively) in response
to PRKD2 silencing (Table 1, Fig. 6). The integrin family of cell
adhesion receptors regulates a diverse array of cellular functions
crucial to carcinogenesis [64] and mediates resistance towards
radio- [65] and chemotherapy [66]. The importance of integrins in
several cell types that affect tumor progression has made them an
appealing target for cancer therapy including glioblastoma [67].
Results of a cilengitide phase II trial in patients with recurrent
glioblastoma showed promising effects [68]. Of note, a splice
variant of human calcium and integrin-binding protein 1a (CIB1a)
was identiﬁed as a PRKD2 substrate that regulates tumor growth
in vivo by promoting angiogenesis [35]. In light of the different
signaling cascades that are elicited by PRKD2 the authors of that
study suggested that targeting of PRKD2 phosphorylation sub-
strates might be more speciﬁc than targeting the kinase itself [35].
Two other genes, namely PLAU (encoding urokinase-type
plasminogen activator; uPA) and PLAUR (encoding uPA receptor;
uPAR) were also downregulated after PRKD2 silencing. uPAR is
frequently expressed at high levels in GBM [69] and promotes
cancer invasion by uPA binding and activation of extracellular
proteases [70]. Silencing of uPA and/or uPAR was shown to inhibit
invasion of GBM cells and xenografts [71]. Attenuation of PRKD2
expression by RNAi during the present study also reduced MMP-1
expression, a matrix metalloproteinase, which is expressed in
GBM but absent in normal brain or low grade astrocytomas [72].
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median patient survival times [72]. A recent report has shown
that silencing of PRKD2 and PRKD3 downregulates uPA, uPAR and
MMP-9 and decreases the invasive potential of prostate cancer
cells [15], ﬁndings compatible with data reported during the
present study. However, in contrast to Zou et al. [15], who have
identiﬁed PRKD2 as a major regulator of the pIKK-IκB-p65 nuclear
translocation pathway that controls prostate cancer invasiveness,
this pathway was unaffected in our study (Fig. 5D).
Recently, Navarro and colleagues investigated T-cell function in
PRKD2 null mice or mice expressing catalytically inactive PRKD2
[73]. These studies revealed that loss of PRKD2 increases thymic
output resulting in lymphoid hyperplasia and splenomegaly
indicating a role for the kinase in thymic homeostasis [73].
Whether and to what extent pharmacological inhibition of PRKD2
in glioblastoma models would interfere with a normal T-cell
response and lead to altered properties of tumor-associated
immune cells remains to be established. Ideally this issue should
be tested with a blood–brain barrier permeable inhibitor of
PRKD2 in a preclinical intracranial animal model of GBM.
Overall, data presented here identify PRKD2 as a potential
kinase target to reduce glioblastoma cell motility and invasion,
two key properties fostering dissemination and recurrence of
GBM. Gene expression analyses point towards a beneﬁcial effect
of PRKD2 silencing leading to the formation of a less motile and
less invasive cellular GBM phenotype.Acknowledgments
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